Ultragenyx Pharmaceutical(US:RARE) Prnewswire·2026-02-25 01:57Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab during the specified class period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][7]. - The complaint alleges that Ultragenyx made false statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with clinical trial results [4][7]. - Investors have until April 6, 2026, to file for lead plaintiff status in the lawsuit [2][9]. Group 2: Stock Performance - On December 29, 2025, Ultragenyx's stock price dropped over 42%, falling from $34.19 per share to $19.72 per share after the company announced that its Phase III studies did not achieve statistical significance [5][7]. Group 3: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss their legal rights [3][10]. - Options for investors include filing to be a lead plaintiff by the deadline or choosing to remain an absent class member [9].